PT  - JOURNAL ARTICLE
AU  - Yanovskiy, Moshe
AU  - Levy, Ori Nissim
AU  - Shaki, Yair Y.
AU  - Zigdon, Avi
AU  - Socol, Yehoshua
TI  - Cost-Effectiveness Threshold for Healthcare and Safety: Justification and Quantification
AID  - 10.1101/2021.04.05.21254927
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.05.21254927
4099  - http://medrxiv.org/content/early/2021/04/09/2021.04.05.21254927.short
4100  - http://medrxiv.org/content/early/2021/04/09/2021.04.05.21254927.full
AB  - Every public expenditure, including saving lives or extending life expectancy of particular persons (target population), has unwanted but unavoidable side effects of statistical shortening of life expectancy of the general public. Therefore, cost-effectiveness analysis in making decisions regarding health and safety is an ethical necessity. We report here cost-effectiveness estimation based on comparison of three independent methods: (1) by analyzing salaries in risky occupations, (2) by assuming that people value their lives twice more than the wealth they earn, and (3) by comparing with the U.S. current legal practice. To the best of our knowledge, nobody applied method (2) to cost-effectiveness analysis. Our result is that the cost-effectiveness threshold for the developed countries is about US$60,000 ± 25,000 per life-year (LY), or about 1.0 ± 0.4 GDP (gross domestic product) per capita per LY. Therefore, a sum of not higher than US$85,000 (1.4 GDP per capita) is statistically sufficient to “purchase” an additional year of life – or, alternatively, to “rob” one year of life if taken away. So, 140% GDP per capita per life-year should be considered as the upper limit of prudent expenditure on healthcare and safety. The result is in excellent correspondence with the existing healthcare policies.HighlightsSafety consumes resources; resources are limitedTherefore, excessive safety expenditure claims more life than it savesPrudent safety expenditure is up to 140% GDP per capita per life-yearCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the Jerusalem College of Technology Grant №5969Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approvals requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A